日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety

皮下注射工程化因子VIIa（激活型）marzeptacog alfa治疗伴有抑制剂的血友病：药代动力学、药效学、疗效和安全性II期临床试验

期刊:Research and Practice in Thrombosis and Haemostasis
影响因子:3.4
doi:10.1002/rth2.12576
Mahlangu, Johnny; Levy, Howard; Kosinova, Marina V; Khachatryan, Heghine; Korczowski, Bartosz; Makhaldiani, Levani; Iosava, Genadi; Lee, Martin; Del Greco, Frank
发表日期：2021
文献求助 收藏

Efficacy, Safety and Pharmacokinetic Results of a Phase III, Open-Label, Multicenter Study with a Plasma-Derived Von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Pediatric Patients <12 Years of Age with Hemophilia A (SWIFTLY-HA Study)

一项针对 12 岁以下 A 型血友病患儿的血浆衍生血管性血友病因子 (VWF)/因子 VIII (FVIII) 浓缩物的 III 期开放标签多中心研究的疗效、安全性和药代动力学结果 (SWIFTLY-HA 研究)

期刊:Journal of Blood Medicine
影响因子:2.7
doi:10.2147/JBM.S299130
Djambas Khayat, Claudia; Iosava, Genadi; Romashevskaya, Irina; Stasyshyn, Oleksandra; Lopez, Marta Julia; Pompa, Maria Teresa; Rogosch, Tobias; Seifert, Wilfried
VWF
发表日期：2021
文献求助 收藏

Pharmacokinetics, Efficacy and Safety of a Plasma-Derived VWF/FVIII Concentrate (Formulation V) in Pediatric Patients with von Willebrand Disease (SWIFTLY-VWD Study)

血浆来源的 VWF/FVIII 浓缩物（配方 V）在患有血管性血友病的儿科患者中的药代动力学、疗效和安全性（SWIFTLY-VWD 研究）

期刊:Journal of Blood Medicine
影响因子:2.7
doi:10.2147/JBM.S236789
Auerswald, Guenter; Djambas Khayat, Claudia; Stasyshyn, Oleksandra; Iosava, Genadi; Romashevskaya, Irina; López, Marta Julia; Seifert, Wilfried; Rogosch, Tobias
VWF
发表日期：2020
文献求助 收藏